Before joining the FDA in 2023 to launch and lead FDA’s TAP Total Product Lifecycle Advisors Program, Ed was Founder and CEO of Shenkan Advisors, a medtech strategic consulting firm from 2009-2022. He focused on strategic plans, M&A due diligence, exit strategies, financial analysis, valuation, and identifying compelling sectors and companies for investment opportunities within the medical device, diagnostics, biopharma, and healthcare service industries.
From 2000-2009, Mr. Shenkan was a sell side securities analyst for J.P. Morgan, Wells Fargo Securities, and Needham. Ed has authored medical device industry reports on Spine, Ophthalmology, Neurovascular, Radiation Therapy, Cardiovascular and Robotics companies and products. As a securities analyst Ed covered companies in medical technology, diagnostic labs, healthcare services, healthcare IT.
His operations experience includes positions in marketing, business development, and district sales management for Schering Plough, a pharmaceutical company. He earned an MBA from Duke University, a B.A. from the University of Pennsylvania, and a B.S. from The Wharton School.
